{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:48:26Z","timestamp":1783079306057,"version":"3.54.6"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC-OX) is an emerging palliative treatment for patients with unresectable colorectal peritoneal metastases. Previously, our study group reported that patients experienced abdominal pain for several weeks after PIPAC-OX. However, it is unknown how this compares to abdominal pain after regular colorectal cancer surgery. To provide some perspective, this study compared the presence of abdominal pain after PIPAC-OX to the presence of abdominal pain after primary tumor surgery. Patient reported abdominal pain scores (EORTC QLQ-CR-29), from two prospective, Dutch cohorts were used in this study. Scores ranged from 0 to 100, a higher score represents more abdominal pain. Abdominal pain at baseline and at four weeks after\u00a0treatment were compared between the two groups. Twenty patients who underwent PIPAC-OX and 322 patients who underwent primary tumor surgery were included in the analysis. At baseline, there were no differences in abdominal pain between both groups (mean 20 vs. 18, respectively; <jats:italic>p<\/jats:italic>\u2009=\u20090.688). Four weeks after treatment, abdominal pain was significantly worse in the PIPAC group (39 vs 15, respectively; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; Cohen\u2019s d\u2009=\u20090.99). The differential effect over time for abdominal pain differed significantly between both groups (mean difference: 19 vs \u2212\u20093, respectively; <jats:italic>p<\/jats:italic>\u2009=\u20090.004; Cohen\u2019s d\u2009=\u20090.88). PIPAC-OX resulted in significantly worse postoperative abdominal pain than primary tumor surgery. These results can be used for patient counseling and stress the need for adequate analgesia during and after PIPAC-OX. Further research is required to prevent or reduce abdominal pain after PIPAC-OX.<\/jats:p><jats:p><jats:italic>Trial registration<\/jats:italic> CRC-PIPAC: Clinicaltrails.gov NCT03246321 (01-10-2017)<\/jats:p>","DOI":"10.1038\/s41598-023-47510-0","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T10:04:16Z","timestamp":1700647456000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparing patient reported abdominal pain between patients treated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC-OX) and primary colorectal cancer surgery"],"prefix":"10.1038","volume":"13","author":[{"given":"Vincent C. J.","family":"van de Vlasakker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin J.","family":"Lurvink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma C.","family":"Wassenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulien","family":"Rauwerdink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Checca","family":"Bakkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen P.","family":"Rovers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia S.","family":"Bonhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus W. A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinus J.","family":"Wiezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djamila","family":"Boerma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon W.","family":"Nienhuijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floortje","family":"Mols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace H. J. T.","family":"de Hingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"47510_CR1","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00464-012-2148-0","volume":"26","author":"W Solass","year":"2012","unstructured":"Solass, W. et al. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg. Endosc. 26, 1849\u20131855 (2012).","journal-title":"Surg. Endosc."},{"key":"47510_CR2","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00464-011-1964-y","volume":"26","author":"W Solass","year":"2012","unstructured":"Solass, W. et al. Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: Proof of concept. Surg. Endosc. 26, 847\u2013852 (2012).","journal-title":"Surg. Endosc."},{"key":"47510_CR3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","volume":"21","author":"W Solass","year":"2014","unstructured":"Solass, W. et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: First evidence for efficacy. Ann. Surg. Oncol. 21, 553\u2013559 (2014).","journal-title":"Ann. Surg. Oncol."},{"key":"47510_CR4","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1245\/s10434-012-2840-2","volume":"20","author":"A Blanco","year":"2013","unstructured":"Blanco, A. et al. Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann. Surg. Oncol. 20, 2311\u20132316 (2013).","journal-title":"Ann. Surg. Oncol."},{"key":"47510_CR5","doi-asserted-by":"crossref","unstructured":"Lurvink, R. J., Rovers, K. P., Nienhuijs, S. W., Creemers, G. J., Burger, J. W. A., de Hingh, I. H. J. T. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) in patients with colorectal peritoneal metastases\u2014A systematic review. J Gastrointest Oncol. Apr; 12(Suppl 1): S242\u2013S25 (2020).","DOI":"10.21037\/jgo-20-257"},{"key":"47510_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-030408","volume":"9","author":"KP Rovers","year":"2019","unstructured":"Rovers, K. P. et al. Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: Protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC). BMJ Open. 9, e030408 (2019).","journal-title":"BMJ Open."},{"key":"47510_CR7","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1245\/s10434-020-09558-4","volume":"28","author":"KP Rovers","year":"2021","unstructured":"Rovers, K. P. et al. Pressurized intraperitoneal aerosol chemtoherapy (oxaliplatin) for unresectable colorectal peritoneal metastases: A multicenter, single-arm, phase II trial (CRC-PIPAC). Ann. Surg. Oncol. 28, 5311\u20135326 (2021).","journal-title":"Ann. Surg. Oncol."},{"key":"47510_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-021-08802-6","author":"RJ Lurvink","year":"2021","unstructured":"Lurvink, R. J. et al. Patient-reported outcomes during repetitive oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for isolated unresectable colorectal peritoneal metastases in a multicenter, single-arm, phase 2 trial (CRC-PIPAC). Surg. Endosc. https:\/\/doi.org\/10.1007\/s00464-021-08802-6 (2021).","journal-title":"Surg. Endosc."},{"issue":"5","key":"47510_CR9","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1093\/bjs\/znab043","volume":"108","author":"M Graversen","year":"2021","unstructured":"Graversen, M., Detlefsen, S., Pfeiffer, P. & Mortensen, M. B. Local peritoneal toxicity from adjuvant pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in high-risk patients with colonic cancer. BJS. 108(5), e187\u2013e188 (2021).","journal-title":"BJS."},{"key":"47510_CR10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s11764-020-00923-6","volume":"15","author":"CS Bonhof","year":"2020","unstructured":"Bonhof, C. S. et al. The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients. J. Cancer Surviv. 15, 190\u2013200 (2020).","journal-title":"J. Cancer Surviv."},{"key":"47510_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson, N. K. et al. The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85, 365\u2013376 (1993).","journal-title":"J. Natl. Cancer Inst."},{"key":"47510_CR12","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s11136-015-1210-5","volume":"25","author":"AM Stiggelbout","year":"2016","unstructured":"Stiggelbout, A. M. et al. The EORTC QLQ-CR29 quality of life questionnaire for colorectal cancer: validation of the Dutch version. Qual. Life Res. 25, 1853\u20131858 (2016).","journal-title":"Qual. Life Res."},{"key":"47510_CR13","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/j.ejca.2009.08.014","volume":"45","author":"RN Whistance","year":"2009","unstructured":"Whistance, R. N. et al. Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life. Eur. J. Cancer. 45, 3017\u20133026 (2009).","journal-title":"Eur. J. Cancer."},{"issue":"9","key":"47510_CR14","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdm056","volume":"18","author":"M Van den Beuken-van Everdingen","year":"2007","unstructured":"Van den Beuken-van Everdingen, M. et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann. Oncol. 18(9), 1437\u20131449 (2007).","journal-title":"Ann. Oncol."},{"issue":"3","key":"47510_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10585-018-9895-9","volume":"35","author":"M Graversen","year":"2018","unstructured":"Graversen, M., Detlefsen, S., Pfeiffer, P., Lundell, L. & Mortensen, M. B. Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): Report of two cases and literature survey. Clin. Exp. Metastasis 35(3), 103\u2013108 (2018).","journal-title":"Clin. Exp. Metastasis"},{"issue":"1","key":"47510_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.7150\/jca.21460","volume":"9","author":"H Teixeira Farinha","year":"2018","unstructured":"Teixeira Farinha, H. et al. Inflammatory response and toxicity after pressurized intraperitoneal aerosol chemotherapy. J. Cancer 9(1), 13\u201320 (2018).","journal-title":"J. Cancer"},{"issue":"4","key":"47510_CR17","doi-asserted-by":"publisher","first-page":"20180128","DOI":"10.1515\/pp-2018-0128","volume":"3","author":"M Graversen","year":"2018","unstructured":"Graversen, M., Lundell, L., Fristrup, C., Pfeiffer, P. & Mortensen, M. B. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as an outpatient procedure. Pleura Peritoneum 3(4), 20180128 (2018).","journal-title":"Pleura Peritoneum"},{"key":"47510_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2020.09.010","volume":"140","author":"F Dumont","year":"2020","unstructured":"Dumont, F. et al. A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers. Eur. J. Cancer 140, 37\u201344 (2020).","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"47510_CR19","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-20-2152","volume":"27","author":"G Kim","year":"2021","unstructured":"Kim, G. et al. PIPAC-OX: A phase I study of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy in patients with peritoneal metastases. Clin. Cancer Res. 27(7), 1875\u20131881 (2021).","journal-title":"Clin. Cancer Res."},{"key":"47510_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12957-016-0892-7","volume":"14","author":"M Robella","year":"2016","unstructured":"Robella, M., Vaira, M. & de Simone, M. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: An innovative approach to treat peritoneal carcinomatosis. World J. Surg. Oncol. 14, 128 (2016).","journal-title":"World J. Surg. Oncol."},{"key":"47510_CR21","doi-asserted-by":"publisher","first-page":"175883591877703","DOI":"10.1177\/1758835918777036","volume":"10","author":"M Graversen","year":"2018","unstructured":"Graversen, M. et al. Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. Ther. Adv. Med. Oncol. 10, 1758835918777036 (2018).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"47510_CR22","doi-asserted-by":"crossref","unstructured":"Taibi, A., Teixeira Farinha, H., Durand Fontanier, S., Sayedalamin, Z., H\u00fcbner, M. & Sgarbura, O. Pressurized intraperitoneal aerosol chemotherapy enhanced by electrostatic precipitation (ePIPAC) for patients with peritoneal metastases. Ann. Surg. Oncol. (2020)","DOI":"10.1245\/s10434-020-09332-6"},{"key":"47510_CR23","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.ejso.2015.06.001","volume":"41","author":"K Odendahl","year":"2015","unstructured":"Odendahl, K. et al. Quality of life of patients with end-stage peritoneal metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Eur. J. Surg. Oncol. 41, 1379\u20131385 (2015).","journal-title":"Eur. J. Surg. Oncol."},{"key":"47510_CR24","doi-asserted-by":"publisher","first-page":"4596176","DOI":"10.1155\/2017\/4596176","volume":"2017","author":"H Teixeira Farinha","year":"2017","unstructured":"Teixeira Farinha, H. et al. Impact of pressurized intraperitoneal aerosol chemotherapy on quality of life and symptoms in patients with peritoneal carcinomatosis: A retrospective cohort study. Gastroenterol. Res. Pract. 2017, 4596176 (2017).","journal-title":"Gastroenterol. Res. Pract."},{"key":"47510_CR25","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/biomedicines8050102","volume":"8","author":"M de Simone","year":"2020","unstructured":"de Simone, M. et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin, cisplatin, and doxorubicin in patients with peritoneal carcinomatosis: an open-label, single-arm, phase II clinical trial. Biomedicines 8, 102 (2020).","journal-title":"Biomedicines"},{"key":"47510_CR26","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09508-0","author":"N Tabchouri","year":"2021","unstructured":"Tabchouri, N. et al. Pressurized intraperitoneal aerosol chemotherapy for colorectal peritoneal metastases. Ann. Surg. Oncol. https:\/\/doi.org\/10.1245\/s10434-020-09508-0 (2021).","journal-title":"Ann. Surg. Oncol."},{"issue":"5","key":"47510_CR27","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1245\/s10434-022-13010-0","volume":"30","author":"M Graversen","year":"2023","unstructured":"Graversen, M. et al. Treatment of peritoneal metastasis with pressurized intraperitoneal aerosol chemotherapy: Results from the prospective PIPAC-OPC2 study. Ann. Surg. Oncol. 30(5), 2634\u20132644 (2023).","journal-title":"Ann. Surg. Oncol."},{"issue":"5","key":"47510_CR28","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.ejso.2020.11.135","volume":"47","author":"R Lurvink","year":"2021","unstructured":"Lurvink, R. et al. Increase in the incidence of synchronous and metachronous peritoneal metastases in patients with colorectal cancer: A nationwide study. Eur. J. Surg. Oncol. 47(5), 1026\u20131033 (2021).","journal-title":"Eur. J. Surg. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47510-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47510-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47510-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T11:10:42Z","timestamp":1700651442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47510-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["47510"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-47510-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]},"assertion":[{"value":"5 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"De Hingh reports an unrestricted research grant from RanD\/QPS and Roche, outside the submitted work, paid to the institute. The other authors have no conflict of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20458"}}